MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino-Kenudson, Taru Muranen, Jessica Tao, Ana Bosch Campos, Jordi Rodon, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Phillip Kim, Cornelia Quadt, Manway Liu, Alan Huang, Neal Rosen, Jeffrey A. EngelmanMaurizio Scaltriti, José Baselga

Research output: Contribution to journalArticlepeer-review

168 Scopus citations


Activating mutations of the PIK3CA gene occur frequently in breast cancer, and inhibitors that are specific for phosphatidylinositol 3-kinase (PI3K) p110a, such as BYL719, are being investigated in clinical trials. In a search for correlates of sensitivity to p110a inhibition among PIK3CA-mutant breast cancer cell lines, we observed that sensitivity to BYL719 (as assessed by cell proliferation) was associated with full inhibition of signaling through the TORC1 pathway. Conversely, cancer cells that were resistant to BYL719 had persistently active mTORC1 signaling, although Akt phosphorylation was inhibited. Similarly, in patients, pS6 (residues 240/4) expression (a marker of mTORC1 signaling) was associated with tumor response to BYL719, and mTORC1 was found to be reactivated in tumors from patients whose disease progressed after treatment. In PIK3CA-mutant cancer cell lines with persistent mTORC1 signaling despite PI3K p110a blockade (that is, resistance), the addition of the allosteric mTORC1 inhibitor RAD001 to the cells alongwith BYL719 resulted in reversal of resistance in vitro and in vivo. Finally, we found that growth factors such as insulin-like growth factor 1 and neuregulin 1 can activatemammalian target of rapamycin (mTOR) and mediate resistance to BYL719. Our findings suggest that simultaneous administration of mTORC1 inhibitors may enhance the clinical activity of p110a-targeted drugs and delay the appearance of resistance.

Original languageEnglish (US)
Article number196ra99
JournalScience translational medicine
Issue number196
StatePublished - Jul 31 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer'. Together they form a unique fingerprint.

Cite this